Delcath Systems Presented Retrospective Comparative Study Of Chemosat And SIRT, Showing Significantly Longer Overall Survival For Patients Treated With Chemosat Vs. SIRT (516 And 301 Days, Respectively; P=0.006) For Metastatic Uveal Melanoma
Benzinga Newsdesk - Sep 11, 2023, 8:17AM